Financhill
Sell
38

ARMP Quote, Financials, Valuation and Earnings

Last price:
$2.01
Seasonality move :
0.79%
Day range:
$1.93 - $2.09
52-week range:
$1.80 - $4.48
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
720.95x
P/B ratio:
--
Volume:
15.3K
Avg. volume:
10K
1-year change:
-48.04%
Market cap:
$72M
Revenue:
--
EPS (TTM):
-$1.64

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ARMP
Armata Pharmaceuticals
$1.6M -$0.35 -- -36.36% --
AIM
AIM ImmunoTech
$100K -$0.09 -23.08% -53.85% $2.75
CATX
Perspective Therapeutics
$297.8K -$0.25 -- -40.08% $15.61
ELMD
Electromed
$15.3M -- 11.77% -- --
PLX
Protalix BioTherapeutics
$18.7M -- 73.62% -- $14.50
XTNT
Xtant Medical Holdings
$31.8M -$0.02 11.16% -33.33% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ARMP
Armata Pharmaceuticals
$1.99 -- $72M -- $0.00 0% 720.95x
AIM
AIM ImmunoTech
$0.15 $2.75 $9.6M -- $0.00 0% 41.33x
CATX
Perspective Therapeutics
$3.14 $15.61 $212.2M -- $0.00 0% 16.96x
ELMD
Electromed
$29.20 -- $247M 40.56x $0.00 0% 4.56x
PLX
Protalix BioTherapeutics
$2.51 $14.50 $184.8M 121.00x $0.00 0% 4.32x
XTNT
Xtant Medical Holdings
$0.59 -- $81.4M -- $0.00 0% 0.68x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ARMP
Armata Pharmaceuticals
-- 3.526 -- --
AIM
AIM ImmunoTech
48.41% 0.854 17.25% 0.71x
CATX
Perspective Therapeutics
-- -3.617 -- --
ELMD
Electromed
-- 2.128 -- 4.99x
PLX
Protalix BioTherapeutics
-- 1.876 -- 1.22x
XTNT
Xtant Medical Holdings
43.2% 0.590 37.09% 0.81x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ARMP
Armata Pharmaceuticals
-- -$9.8M -- -- -- -$9.2M
AIM
AIM ImmunoTech
$27K -$4.5M -219.06% -256.33% -9994.29% -$3.3M
CATX
Perspective Therapeutics
-- -$18.6M -- -- -- -$26.3M
ELMD
Electromed
$11.5M $1.9M 15.62% 15.62% 13.21% $2.3M
PLX
Protalix BioTherapeutics
$9.6M $4M -19.69% -29.54% 23.06% $4M
XTNT
Xtant Medical Holdings
$16.3M -$3.8M -22.96% -35.98% -13.47% -$3.8M

Armata Pharmaceuticals vs. Competitors

  • Which has Higher Returns ARMP or AIM?

    AIM ImmunoTech has a net margin of -- compared to Armata Pharmaceuticals's net margin of -10571.43%. Armata Pharmaceuticals's return on equity of -- beat AIM ImmunoTech's return on equity of -256.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARMP
    Armata Pharmaceuticals
    -- -$0.15 --
    AIM
    AIM ImmunoTech
    77.14% -$0.06 $5.6M
  • What do Analysts Say About ARMP or AIM?

    Armata Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 251.76%. On the other hand AIM ImmunoTech has an analysts' consensus of $2.75 which suggests that it could grow by 1728.46%. Given that AIM ImmunoTech has higher upside potential than Armata Pharmaceuticals, analysts believe AIM ImmunoTech is more attractive than Armata Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARMP
    Armata Pharmaceuticals
    0 0 0
    AIM
    AIM ImmunoTech
    1 0 0
  • Is ARMP or AIM More Risky?

    Armata Pharmaceuticals has a beta of 0.873, which suggesting that the stock is 12.738% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of -0.292, suggesting its less volatile than the S&P 500 by 129.237%.

  • Which is a Better Dividend Stock ARMP or AIM?

    Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARMP or AIM?

    Armata Pharmaceuticals quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Armata Pharmaceuticals's net income of -$5.5M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 720.95x versus 41.33x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARMP
    Armata Pharmaceuticals
    720.95x -- -- -$5.5M
    AIM
    AIM ImmunoTech
    41.33x -- $35K -$3.7M
  • Which has Higher Returns ARMP or CATX?

    Perspective Therapeutics has a net margin of -- compared to Armata Pharmaceuticals's net margin of --. Armata Pharmaceuticals's return on equity of -- beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ARMP
    Armata Pharmaceuticals
    -- -$0.15 --
    CATX
    Perspective Therapeutics
    -- -$0.21 --
  • What do Analysts Say About ARMP or CATX?

    Armata Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 251.76%. On the other hand Perspective Therapeutics has an analysts' consensus of $15.61 which suggests that it could grow by 411.15%. Given that Perspective Therapeutics has higher upside potential than Armata Pharmaceuticals, analysts believe Perspective Therapeutics is more attractive than Armata Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARMP
    Armata Pharmaceuticals
    0 0 0
    CATX
    Perspective Therapeutics
    7 1 0
  • Is ARMP or CATX More Risky?

    Armata Pharmaceuticals has a beta of 0.873, which suggesting that the stock is 12.738% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.220, suggesting its more volatile than the S&P 500 by 22.033%.

  • Which is a Better Dividend Stock ARMP or CATX?

    Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARMP or CATX?

    Armata Pharmaceuticals quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Armata Pharmaceuticals's net income of -$5.5M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 720.95x versus 16.96x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARMP
    Armata Pharmaceuticals
    720.95x -- -- -$5.5M
    CATX
    Perspective Therapeutics
    16.96x -- -- -$15.1M
  • Which has Higher Returns ARMP or ELMD?

    Electromed has a net margin of -- compared to Armata Pharmaceuticals's net margin of 10.05%. Armata Pharmaceuticals's return on equity of -- beat Electromed's return on equity of 15.62%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARMP
    Armata Pharmaceuticals
    -- -$0.15 --
    ELMD
    Electromed
    78.34% $0.16 $41.5M
  • What do Analysts Say About ARMP or ELMD?

    Armata Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 251.76%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 13.01%. Given that Armata Pharmaceuticals has higher upside potential than Electromed, analysts believe Armata Pharmaceuticals is more attractive than Electromed.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARMP
    Armata Pharmaceuticals
    0 0 0
    ELMD
    Electromed
    0 0 0
  • Is ARMP or ELMD More Risky?

    Armata Pharmaceuticals has a beta of 0.873, which suggesting that the stock is 12.738% less volatile than S&P 500. In comparison Electromed has a beta of 0.334, suggesting its less volatile than the S&P 500 by 66.566%.

  • Which is a Better Dividend Stock ARMP or ELMD?

    Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARMP or ELMD?

    Armata Pharmaceuticals quarterly revenues are --, which are smaller than Electromed quarterly revenues of $14.7M. Armata Pharmaceuticals's net income of -$5.5M is lower than Electromed's net income of $1.5M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Electromed's PE ratio is 40.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 720.95x versus 4.56x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARMP
    Armata Pharmaceuticals
    720.95x -- -- -$5.5M
    ELMD
    Electromed
    4.56x 40.56x $14.7M $1.5M
  • Which has Higher Returns ARMP or PLX?

    Protalix BioTherapeutics has a net margin of -- compared to Armata Pharmaceuticals's net margin of 18.02%. Armata Pharmaceuticals's return on equity of -- beat Protalix BioTherapeutics's return on equity of -29.54%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARMP
    Armata Pharmaceuticals
    -- -$0.15 --
    PLX
    Protalix BioTherapeutics
    53.37% $0.03 $32.4M
  • What do Analysts Say About ARMP or PLX?

    Armata Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 251.76%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 477.69%. Given that Protalix BioTherapeutics has higher upside potential than Armata Pharmaceuticals, analysts believe Protalix BioTherapeutics is more attractive than Armata Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARMP
    Armata Pharmaceuticals
    0 0 0
    PLX
    Protalix BioTherapeutics
    0 0 0
  • Is ARMP or PLX More Risky?

    Armata Pharmaceuticals has a beta of 0.873, which suggesting that the stock is 12.738% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.747, suggesting its less volatile than the S&P 500 by 25.306%.

  • Which is a Better Dividend Stock ARMP or PLX?

    Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARMP or PLX?

    Armata Pharmaceuticals quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18M. Armata Pharmaceuticals's net income of -$5.5M is lower than Protalix BioTherapeutics's net income of $3.2M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 121.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 720.95x versus 4.32x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARMP
    Armata Pharmaceuticals
    720.95x -- -- -$5.5M
    PLX
    Protalix BioTherapeutics
    4.32x 121.00x $18M $3.2M
  • Which has Higher Returns ARMP or XTNT?

    Xtant Medical Holdings has a net margin of -- compared to Armata Pharmaceuticals's net margin of -17.98%. Armata Pharmaceuticals's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.98%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARMP
    Armata Pharmaceuticals
    -- -$0.15 --
    XTNT
    Xtant Medical Holdings
    58.37% -$0.04 $80.5M
  • What do Analysts Say About ARMP or XTNT?

    Armata Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 251.76%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 284.09%. Given that Xtant Medical Holdings has higher upside potential than Armata Pharmaceuticals, analysts believe Xtant Medical Holdings is more attractive than Armata Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARMP
    Armata Pharmaceuticals
    0 0 0
    XTNT
    Xtant Medical Holdings
    0 0 0
  • Is ARMP or XTNT More Risky?

    Armata Pharmaceuticals has a beta of 0.873, which suggesting that the stock is 12.738% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.361, suggesting its less volatile than the S&P 500 by 63.871%.

  • Which is a Better Dividend Stock ARMP or XTNT?

    Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARMP or XTNT?

    Armata Pharmaceuticals quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. Armata Pharmaceuticals's net income of -$5.5M is lower than Xtant Medical Holdings's net income of -$5M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 720.95x versus 0.68x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARMP
    Armata Pharmaceuticals
    720.95x -- -- -$5.5M
    XTNT
    Xtant Medical Holdings
    0.68x -- $27.9M -$5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Will Palantir Stock Be Worth in 2030?
What Will Palantir Stock Be Worth in 2030?

Palantir Technologies (NYSE: PLTR) has emerged from a growth slowdown…

Is Rollins Stock a Buy, Sell or Hold?
Is Rollins Stock a Buy, Sell or Hold?

Pest control giant Rollins (NYSE:ROL) is the parent company of…

Why Did Bill Ackman Buy Uber?
Why Did Bill Ackman Buy Uber?

In early 2025, billionaire investor Bill Ackman, CEO of Pershing…

Stock Ideas

Buy
59
Is AAPL Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 38x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 111x

Sell
43
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
65
ATEX alert for Feb 12

Anterix [ATEX] is down 0.72% over the past day.

Buy
87
GDS alert for Feb 12

GDS Holdings [GDS] is up 0.32% over the past day.

Sell
30
SPSC alert for Feb 12

SPS Commerce [SPSC] is up 0.17% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock